human
metapneumoviru
hmpv
infect
caus
acut
respiratori
tract
infect
rti
result
hospit
children
adult
date
antivir
vaccin
avail
common
viral
infect
immunomodul
could
repres
interest
strategi
treatment
sever
viral
infect
recent
role
proteaseactiv
receptor
par
inflamm
coagul
infect
process
grow
interest
herein
effect
agonist
antagonist
hmpv
infect
investig
balbc
mice
intranas
administr
agonist
result
increas
weight
loss
mortal
infect
mice
convers
antagonist
benefici
hmpv
infect
decreas
weight
loss
clinic
sign
significantli
reduc
pulmonari
inflamm
proinflammatori
cytokin
level
includ
kc
recruit
immun
cell
lung
addit
signific
reduct
pulmonari
viral
titer
also
observ
lung
antagonisttr
mice
despit
appar
direct
effect
viru
replic
vitro
experi
import
role
regul
furin
express
lung
shown
first
time
experi
indic
hmpv
fusion
protein
cleav
furin
thu
suggest
could
effect
viral
infect
addit
immunomodulatori
properti
thu
inhibit
select
antagonist
could
repres
interest
strategi
decreas
sever
paramyxoviru
infect
human
metapneumoviru
hmpv
paramyxoviru
respons
acut
respiratori
tract
infect
especi
sever
young
children
elderli
peopl
immunocomprom
individu
limit
report
human
extens
studi
anim
shown
sever
hmpv
infect
associ
disrupt
epitheli
architectur
presenc
inflammatori
infiltr
around
within
alveoli
among
divers
small
anim
model
evalu
balbc
mice
emerg
excel
model
recapitul
hmpv
infect
includ
effici
viral
replic
lung
concomit
pulmonari
inflamm
airway
obstruct
well
diseas
sever
correl
increas
viral
inoculum
balbc
mous
studi
also
shown
immun
respons
hmpv
infect
disproportion
ineffici
character
weak
innat
respons
adapt
immun
respons
lead
impair
viru
clearanc
prolong
pulmonari
inflamm
date
vaccin
specif
antivir
agent
avail
treatment
hmpv
infect
ribavirin
nucleosid
analogu
licens
treatment
sever
human
respiratori
syncyti
viru
hrsv
infect
exhibit
moder
vitro
activ
hmpv
found
benefici
mous
model
inde
antivir
use
treat
sever
case
hmpv
pneumonia
immunocompromis
individu
mechan
action
ribavirin
appear
limit
disrupt
viral
purin
metabol
inhibit
viral
rna
polymeras
shown
drug
could
also
upregul
downregul
cytokin
vitro
suggest
immunomodulatori
well
antivir
effect
howev
ribavirin
associ
mani
sideeffect
teratogen
limit
widespread
use
thu
develop
new
antivir
andor
immunomodulatori
strategi
warrant
treatment
sever
hmpv
infect
secretori
serin
proteas
long
known
play
import
role
sever
physiolog
process
hemostasi
primari
hemostasi
coagul
fibrinolysi
immun
respons
infect
increas
interact
two
system
discov
includ
viral
infect
serin
proteas
coagul
cascad
thrombin
abl
activ
complement
compon
regul
cell
function
activ
famili
gprotein
coupl
receptor
call
proteaseactiv
receptor
par
par
uniqu
mechan
activ
irrevers
proteolyt
cleavag
within
extracellular
nterminu
receptor
expos
new
ntermin
sequenc
act
tether
ligand
latter
interact
second
extracellular
loop
receptor
herebi
activ
receptor
four
par
character
activ
thrombin
except
main
activ
proteas
trypsin
particular
ubiquit
receptor
present
platelet
endotheli
epitheli
cell
neuron
fibroblast
smooth
muscl
cell
leukocyt
tumor
cell
line
receptor
involv
mani
physiolog
process
includ
cardiovascular
respiratori
central
nervou
system
well
embryogenesi
cancer
inflamm
fact
antagonist
current
clinic
trial
antiplatelet
activ
role
pathogenesi
infecti
diseas
recent
investig
number
pathogen
includ
felin
immunodefici
viru
mycobacterium
tuberculosi
dengu
viru
herp
simplex
viru
influenza
viru
latter
pathogen
upregul
observ
airway
mice
infect
highli
pathogen
influenza
viru
base
observ
hypothes
could
also
play
import
role
modul
immun
respons
sever
hmpv
infect
therefor
treat
hmpvinfect
balbc
mice
either
select
agonist
tfllrnh
antagonist
evalu
diseas
sever
observ
activ
increas
weight
loss
decreas
surviv
hmpv
mous
model
contrast
administr
antagonist
decreas
diseas
sever
significantli
reduc
lung
cytokin
inflamm
balbc
mice
protect
effect
antagonist
could
also
explain
decreas
furinmedi
cleavag
viral
fusion
f
protein
sought
investig
whether
agonist
antagonist
effect
viral
replic
vitro
first
experi
uninfect
monolay
preincub
compound
infect
howev
cell
monolay
detach
concentr
antagonist
possibl
due
proapoptot
effect
reagent
toxic
vehicl
dmso
toxic
observ
use
concentr
agonist
tfllrnh
use
concentr
antagonist
agonist
antivir
effect
observ
second
experi
hmpv
preincub
compound
maximum
concentr
addit
monolay
antivir
effect
observ
compound
remov
replac
fresh
medium
adsorpt
phase
compound
replenish
daili
throughout
experi
shown
first
vivo
experi
balbc
mice
infect
intranas
hmpv
tcid
mock
infect
simultan
treat
intranas
period
day
singl
daili
dose
agonist
tfllrnh
antagonist
agonistor
antagonisttreat
uninfect
mice
induc
weight
loss
mortal
sign
toxic
data
shown
mortal
observ
treat
mice
day
post
infect
pi
day
pi
mice
treat
agonist
respect
group
also
greater
weight
loss
compar
infect
vehicletr
mice
figur
convers
weight
loss
significantli
reduc
dosedepend
manner
antagonisttr
mice
compar
infect
vehicletr
group
figur
signific
differ
pulmonari
viral
titer
observ
agonisttr
mice
vehicletr
control
contrast
viral
titer
lung
antagonisttr
mice
significantli
lower
vehicletr
mice
log
figur
thu
conclud
play
deleteri
role
pathogenesi
hmpv
infect
preliminari
experi
observ
treatment
antagonist
reduc
weight
loss
dosedepend
manner
order
evalu
longer
treatment
pronounc
effect
compound
administ
singl
daili
dose
day
start
time
infect
antagonisttreat
uninfect
mice
induc
weight
loss
mortal
sign
toxic
antagonisttr
infect
mice
remain
asymptomat
ie
show
weight
loss
reduc
activ
ruffl
fur
throughout
experi
figur
find
confirm
second
experi
use
mice
per
group
data
shown
moreov
day
pi
signific
decreas
pulmonari
inflamm
observ
treat
mice
figur
correl
signific
decreas
proinflammatori
cytokin
level
figur
addit
viral
replic
lung
day
pi
significantli
reduc
log
antagonisttr
mice
compar
control
confirm
result
previou
experi
figur
thu
conclud
block
protect
mice
symptomat
hmpv
diseas
immun
cell
popul
present
lung
day
pi
analyz
flow
cytometri
mice
treat
day
group
mice
infect
intranas
hmpv
tcid
mock
infect
simultan
treat
day
singl
daili
dose
agonist
tfllrnh
antagonist
respect
vehicl
b
weight
loss
mortal
monitor
daili
day
mice
treat
agonist
antagonist
respect
horizont
bar
underneath
graphic
indic
time
durat
treatment
arrow
number
indic
mice
reach
endpoint
sacrif
full
line
mice
treat
agonist
dot
line
mice
treat
agonist
signific
differ
weight
loss
observ
mice
treat
compound
compar
untreat
mice
base
twoway
anova
p
p
p
p
p
c
viral
titer
determin
tcid
lung
homogen
day
pi
signific
differ
observ
treat
untreat
mice
determin
oneway
anova
p
p
bar
indic
lower
limit
detect
doi
start
time
infect
antagonist
figur
immun
cell
popul
analyz
includ
activ
dendrit
cell
lo
lo
iaie
macrophag
hi
lymphocyt
neutrophil
hi
significantli
reduc
popul
activ
dendrit
cell
macrophag
tlymphocyt
observ
lung
antagonisttr
mice
compar
hmpvinfect
untreat
mice
although
appear
decreas
neutrophil
infect
untreat
mice
event
extrem
low
popul
longer
follow
gaussian
distribut
therefor
reluct
draw
definit
conclus
specif
popul
result
confirm
antagonist
protect
mice
potenti
deleteri
lung
inflamm
induc
hmpv
infect
group
mice
infect
intranas
hmpv
tcid
mock
infect
simultan
treat
day
singl
daili
dose
antagonist
respect
vehicl
weight
loss
mortal
monitor
daili
basi
day
horizont
bar
underneath
graphic
indic
time
durat
treatment
indic
signific
differ
antagonist
treat
mice
untreat
control
base
twoway
anova
p
p
b
day
pi
mice
per
group
euthan
lung
remov
fix
embed
section
stain
histopatholog
degre
inflamm
determin
use
semiquantit
scale
bronchialendobronchi
inflamm
b
peribronchi
inflamm
c
perivascular
inflamm
interstiti
inflamm
e
pleural
inflamm
f
intraalveolar
inflamm
signific
differ
pulmonari
histopatholog
score
observ
treat
untreat
mice
base
twoway
anova
p
c
pulmonari
cytokinechemokin
level
lung
homogen
determin
luminex
kc
rant
data
remov
graph
sinc
detect
valu
obtain
cytokin
group
signific
differ
pulmonari
proinflammatori
cytokinechemokin
level
observ
treat
untreat
mice
base
twoway
anova
p
viral
titer
determin
lung
homogen
signific
differ
pulmonari
viral
titer
observ
antagonisttr
mice
infect
untreat
mice
base
student
ttest
p
proprotein
convertas
especi
furin
shown
process
number
cell
surfac
glycoprotein
infecti
virus
singl
pair
basic
residu
minim
cleavag
site
exhibit
arg
residu
order
tent
investig
possibl
mechan
compound
influenc
viral
replic
analyz
furin
transcript
lung
hmpvinfect
anim
rtpcr
compound
administ
day
dose
start
time
infect
lung
harvest
day
pi
hmpv
infect
result
signific
increas
furin
transcript
mous
lung
compar
uninfect
mice
fig
treatment
infect
mice
agonist
significantli
alter
furin
express
howev
treatment
infect
mice
antagonist
significantli
reduc
furin
transcript
level
compar
hmpvinfect
untreat
mice
use
pire
vector
express
proprotein
convertas
previous
show
similar
express
convertas
abil
cleav
select
substrat
thu
use
construct
show
furin
test
proprotein
convertas
abl
cleav
hmpv
fusion
precursor
protein
activ
form
figur
two
cell
line
investig
effect
cleavag
hmpv
fusion
precursor
protein
figur
vitro
cleavag
assay
treatment
f
proteinfurin
cotransfect
cell
either
agonist
antagonist
alter
f
cleavag
cleavag
respect
compar
howev
cotransfect
cell
cdna
encod
f
protein
furin
well
recombin
human
reduc
f
cleavag
express
cotransfect
cell
treat
antagonist
f
protein
cleavag
remain
low
wherea
agonist
treatment
restor
f
protein
cleavag
basal
level
observ
cell
without
express
confirm
role
cleavag
hmpv
fusion
protein
studi
show
activ
increas
weight
loss
mortal
mous
model
hmpv
infect
convers
antagonist
prevent
clinic
sign
reduc
lung
inflamm
viral
titer
administ
time
viral
infect
reduct
lung
viral
titer
antagonist
probabl
due
direct
antivir
effect
like
mediat
reduct
furin
express
andor
activ
viral
infect
hmpv
infect
caus
wide
spectrum
diseas
mild
upper
respiratori
tract
infect
rti
sever
lower
rti
bronchiol
pneumonia
result
hospit
children
adult
hmpv
one
promin
respiratori
pathogen
children
account
pediatr
hospit
respiratori
tract
infect
recent
studi
estim
hospit
rate
hmpv
older
adult
per
resid
rate
similar
hrsv
influenza
hospit
patient
current
treat
symptomat
sinc
specif
prophylact
therapeut
modal
avail
although
approv
indic
ribavirin
administ
antivir
agent
sever
case
hmpv
pneumonia
variabl
outcom
sever
hmpv
vaccin
investig
anim
model
includ
liveattenu
subunit
vaccin
howev
vaccineinduc
immun
often
partial
protect
andor
wane
rapidli
importantli
hmpvinactiv
vaccin
shown
induc
enhanc
diseas
upon
infect
reminisc
hrsvinactiv
vaccin
clearli
altern
approach
manag
hmpv
infect
need
use
agonist
tfllrnh
antagonist
investig
role
receptor
hmpv
infect
investig
agonist
specif
examin
wellknown
effect
intestin
permeabl
wildtyp
mice
end
credta
infus
colon
mice
effect
agonist
passag
credta
blood
reflect
intestin
permeabl
measur
figur
expect
mice
treat
agonist
peptid
tfllr
display
enhanc
intestin
permeabl
compar
salin
control
treat
mice
mark
contrast
mous
treatment
rllft
inact
control
peptid
effect
permeabl
argu
potenti
nonspecif
effect
agonist
importantli
effect
agonist
increas
intestin
permeabl
abolish
mice
altogeth
result
show
agonist
specif
activ
mice
furthermor
agonist
peptid
also
use
specif
activ
mice
elsewher
subsequ
also
investig
whether
antagonist
capabl
block
specif
signal
vivo
found
antagonist
treatment
prevent
increas
intestin
permeabl
associ
administr
agonist
peptid
wildtyp
mice
figur
thu
effect
antagonist
like
relat
abil
specif
block
vivo
furthermor
antagonist
also
use
block
activ
rodent
model
elsewher
mous
model
inhibit
activ
use
antagonist
clearli
benefici
decreas
sever
hmpv
diseas
strikingli
treatment
start
simultan
hmpvinfect
continu
day
weight
loss
clinic
sign
observ
figur
evalu
pulmonari
inflamm
viral
titer
perform
day
pi
time
point
paramet
peak
untreat
hmpvinfect
mice
acut
phase
infect
pulmonari
inflamm
mostli
consist
interstiti
perivascular
alveolar
inflamm
paramet
significantli
reduc
treatment
antagonist
line
observ
also
show
signific
reduct
level
key
cytokineschemokin
usual
increas
hmpv
infect
includ
kc
rant
cytokin
name
human
equival
murin
kc
previous
shown
upregul
activ
downregul
inhibit
noninfect
human
respiratori
epitheli
cell
model
asthma
idiopath
pulmonari
fibrosi
furthermor
significantli
reduc
express
tuberculosi
cell
vitro
final
khoufach
et
al
recent
demonstr
treatment
influenza
ainfect
mice
also
significantli
reduc
kc
rant
level
bronchoalveolar
lavag
investig
immun
cell
popul
activ
dendrit
cell
macrophag
lymphocyt
neutrophil
lung
hmpvinfect
mice
treat
antagonist
day
pi
use
flow
cytometri
observ
signific
differ
pulmonari
neutrophil
infect
intranas
hmpv
tcid
mock
infect
simultan
treat
day
singl
daili
dose
agonist
tfllrnh
antagonist
mice
sacrif
day
pi
lung
remov
snap
frozen
rna
extract
furin
transcript
level
determin
use
rtpcr
signific
differ
furin
transcript
level
observ
treat
untreat
mice
base
student
ttest
p
b
cell
cotransfect
plasmid
encod
hmpv
f
protein
contain
plasmid
encod
one
proprotein
convertas
cell
lysat
analyz
western
blot
use
mab
furin
convertas
capabl
cleav
full
length
precursor
protein
activ
form
result
shorter
ctermin
subunit
c
recombin
human
furin
cotranfect
hmpv
f
protein
contain
cell
withwithout
agonist
antagonist
western
blot
analysi
cell
lysat
use
mab
shown
doi
group
howev
antagonist
treatment
significantli
reduc
recruit
lung
macrophag
figur
express
human
murin
dendrit
cell
activ
induc
releas
cell
moreov
signal
dendrit
cell
shown
sustain
lethal
lpsinduc
inflammatori
respons
mice
studi
also
observ
signific
reduct
dendrit
cell
present
lung
antagonisttr
mice
compar
untreat
hmpvinfect
mice
activ
human
cell
induc
secret
may
effect
cell
receptor
signal
addit
cell
migrat
liver
mice
reduc
model
liver
fibrosi
suggest
role
cell
migrat
observ
signific
differ
lymphocyt
group
yet
significantli
less
tlymphocyt
found
lung
antagonisttr
mice
remain
confirm
howev
whether
lymphocyt
repres
cytolyt
lymphocyt
provid
evid
block
protect
hmpv
infect
evalu
effect
anoth
antagonist
outcom
hmpv
infect
mous
model
use
control
figur
treat
group
hmpvinfect
mice
show
reduc
weight
loss
although
reduct
import
fact
case
first
experi
weight
mice
remain
similar
uninfect
mice
reduc
activ
ruffl
fur
observ
treatment
either
antagonist
also
reduc
mortal
induc
hmpv
infect
compar
mortal
rate
untreat
group
mortal
rate
observ
group
respect
thu
result
confirm
block
protect
hmpv
infect
immunomodul
therapi
offer
sever
advantag
convent
antivir
strategi
host
target
therapi
immunomodul
avoid
select
pressur
pathogen
lead
develop
antimicrobi
resist
addit
nonspecif
natur
innat
immun
system
modul
could
result
broadspectrum
protect
wide
rang
microbi
pathogen
use
immunomodul
viral
infect
extens
investig
chronic
infect
hiv
viral
hepat
infect
agent
like
interferon
clinic
use
advent
sever
respiratori
distress
syndrom
due
avian
influenza
sarscoronaviru
infect
particular
sinc
influenza
pandem
interest
immunomodul
acut
viral
infect
increas
sever
antiinflammatori
therapi
influenza
infect
evalu
far
includ
sphingosin
analogu
inhibitor
antimicrobi
peptid
inhibitor
macrolid
latter
antibiot
known
antiinflammatori
immunomodulatori
properti
shown
promis
result
sever
viral
respiratori
infect
caus
influenza
rhinoviru
hrsv
like
macrolid
antagonist
may
broad
spectrum
activ
inde
khoufach
et
al
recent
report
result
similar
murin
model
influenza
infect
includ
caus
oseltamivirresist
strain
addit
unpublish
data
group
indic
antagonist
significantli
decreas
hrsv
lung
titer
key
pulmonari
cytokin
rant
similar
mous
model
highlight
broadspectrum
potenti
compound
found
antagonisttr
infect
mice
reduc
pulmonari
viral
titer
day
pi
observ
suggest
direct
indirect
effect
viral
replic
direct
antivir
effect
observ
vitro
cell
cultur
experi
although
test
limit
cytotox
complet
rule
direct
antivir
effect
hand
viral
entri
host
cell
mediat
hmpv
f
surfac
glycoprotein
protein
synthes
inact
precursor
protein
requir
proteolyt
cleavag
becom
activ
cleavag
motif
hmpv
f
protein
contain
minim
furin
cleavag
site
ie
present
mani
vivo
substrat
even
though
cleavag
hmpv
f
protein
requir
addit
trypsin
vitro
enzym
could
involv
activ
f
protein
vivo
inde
found
furin
express
level
significantli
increas
lung
hmpvinfect
mice
compar
mockinfect
mice
addit
use
vitro
cleavag
assay
clearli
show
first
time
test
proprotein
convertas
furin
capabl
cleav
hmpv
f
precursor
protein
moreov
express
recombin
human
reduc
f
protein
cleavag
assay
wherea
treatment
express
cell
agonist
restor
f
protein
cleavag
treatment
antagonist
sinc
activ
quickli
initi
intern
degrad
receptor
hypothes
presenc
unactiv
cell
surfac
inhibit
furinmedi
f
protein
cleavag
vitro
observ
could
least
partli
explain
slight
reduct
viral
titer
observ
lung
hmpvinfect
antagonisttr
mice
consid
endogen
activ
present
vivo
infect
inhibit
activ
antagonist
subsequ
inhibit
intern
degrad
could
lead
reduc
f
cleavag
could
therefor
contribut
decreas
hmpv
infect
taken
togeth
data
suggest
furin
level
andor
activ
could
effect
hmpv
infect
similar
note
antagonist
shown
decreas
plasminmedi
cleavag
influenza
hemagglutinin
protein
subsequ
reduct
mous
lung
viral
titer
although
modul
furin
level
andor
activ
subsequ
effect
viral
infect
could
offer
possibl
explan
reduc
viral
titer
observ
lung
antagonisttr
mice
need
confirm
inhibit
reduc
infect
hmpv
strain
well
interest
replic
sever
paramyxovirus
furindepend
immunomodulatori
approach
may
thu
benefici
hmpv
paramyxoviru
infect
well
conclus
report
inhibit
use
nonpeptid
antagonist
benefici
hmpvinfect
mice
protect
mechan
confer
antagonist
mediat
modul
innat
adapt
immun
respons
also
possibl
reduct
viral
infect
differ
antagonist
appear
confer
differ
protect
level
hmpv
infect
warrant
evalu
inhibitor
importantli
assess
delay
treatment
clinic
outcom
importantli
inhibitor
alreadi
clinic
trial
indic
could
acceler
develop
compound
context
acut
treatment
viral
infect
cell
atcc
maintain
minim
essenti
medium
mem
life
technolog
carlsbad
ca
supplement
fetal
bovin
serum
fb
wisent
quebec
qc
hmpv
group
strain
clinic
isol
passag
nine
ten
time
grown
cell
optimem
life
technolog
carlsbad
ca
supplement
trypsin
sigma
st
loui
mo
viru
stock
concentr
column
fisher
scientif
waltham
previous
describ
protocol
use
flask
uninfect
cell
mockinfect
mice
viral
titer
determin
serial
dilut
viru
plate
contain
cell
previous
describ
viru
titer
report
tissu
cultur
infecti
dose
tcid
per
ml
tcid
valu
calcul
reed
muench
method
agonist
tfllrnh
genscript
piscataway
nj
reconstitut
h
concentr
mm
aliquot
store
immedi
intranas
administr
compound
dilut
optimem
control
h
dilut
optimem
administr
antagonist
vorapaxar
axon
medchem
groningen
netherland
reconstitut
stock
concentr
mm
dmso
store
immedi
intranas
administr
compound
dilut
optimem
control
dmso
dilut
optimem
administr
first
experi
confluent
cell
incub
h
dilut
compound
subsequ
cell
wash
pb
infect
tcid
hmpv
h
medium
contain
viru
remov
replac
fresh
infect
medium
trypsin
ad
day
post
infect
pi
titer
determin
day
pi
second
experi
hmpv
preincub
dilut
compound
h
transfer
onto
confluent
monolay
cell
five
hour
later
medium
remov
replac
fresh
infect
medium
contain
dilut
compound
dilut
compound
ad
daili
trypsin
ad
day
pi
titer
determin
day
pi
cell
atcc
cotransfect
cdna
f
protein
hmpv
strain
tag
cterminu
cdna
encod
follow
proprotein
convertas
furin
withwithout
cdna
encod
ratio
hmpv
pc
doubl
transfect
ratio
hmpv
pc
tripl
transfect
twenti
hr
posttransfect
cell
treat
agonist
tfllrnh
antagonist
h
incub
h
fresh
serumfre
media
protein
lysat
transfect
separ
sdspage
follow
western
blot
analysi
mab
report
quantit
perform
use
imagej
softwar
nation
institut
health
normal
report
lung
remov
day
pi
snap
frozen
liquid
nitrogen
rna
extract
use
trizolchloroform
rna
qualiti
verifi
agaros
gel
cdna
prepar
use
ng
total
rna
quantit
pcr
perform
platform
stratagen
santa
clara
ca
use
quanta
sybergreen
vwr
radnor
pa
cdna
synthesi
qpcr
perform
previous
describ
specif
primer
sit
neighbor
exon
use
simultan
amplif
normal
cdna
ribosom
protein
four
sixweekold
balbc
mice
charl
river
laboratori
infect
intranas
tcid
hmpv
optimem
control
balbc
mice
mock
infect
mice
treat
intranas
agonist
tfllrnh
antagonist
equival
dilut
h
dmso
depend
compound
anim
hous
group
three
five
microisol
cage
anim
evalu
daili
basi
weight
loss
presenc
clinic
sign
reduc
activ
ruffl
fur
human
endpoint
determin
weight
loss
accord
guidelin
provid
anim
protect
committe
centr
hospitali
universitair
de
day
pi
six
mice
per
group
euthan
use
sodium
pentobarbit
lung
remov
evalu
viral
titer
cell
cultur
cytokin
level
use
beadbas
multiplex
immunoassay
histopatholog
chang
use
hematoxylineosin
stain
cell
recruit
flow
cytometri
furin
express
level
quantit
rtpcr
male
mice
week
old
charl
river
laboratori
quebec
canada
hous
control
environ
humid
h
photoperiod
free
access
food
water
first
protocol
h
fast
light
halothan
anaesthesia
polyethylen
cathet
insert
intrarect
cm
anu
singl
administr
perform
distal
colon
cathet
volum
three
hour
later
deep
anaesthesia
ketamin
mgkg
xylazin
mgkg
mice
receiv
intracolon
infus
credta
cpmh
h
intestin
permeabl
assess
measur
passag
credta
colon
lumen
blood
blood
collect
cardiac
punctur
measur
count
use
gamma
counter
second
protocol
h
fast
mice
receiv
intraperiton
inject
antagonist
vehicl
carboxymethyl
cellulos
one
h
later
light
halothan
anaesthesia
polyethylen
cathet
insert
intrarect
cm
anu
singl
administr
salin
perform
distal
colon
cathet
volum
three
hour
later
deep
anaesthesia
ketamin
mgkg
xylazin
mgkg
mice
receiv
intracolon
infus
credta
cpmh
h
intestin
permeabl
assess
measur
passag
credta
colon
lumen
blood
blood
collect
cardiac
punctur
measur
count
use
gamma
counter
present
studi
balbc
mice
approv
anim
protect
committe
centr
hospitali
universitair
de
accord
guidelin
canadian
council
anim
care
cpac
studi
mice
conduct
standard
canadian
council
anim
care
approv
anim
care
committe
univers
calgari
lung
remov
day
pi
snap
frozen
liquid
nitrogen
lung
subsequ
weigh
homogen
ml
pb
centrifug
rpm
min
supernat
use
determin
viral
titer
report
tcid
aliquot
lung
homogen
ad
mm
kpo
ph
buffer
contain
chap
sigma
st
loui
mo
proteas
inhibitor
cocktail
sigma
st
loui
mo
store
day
experi
sampl
centrifug
g
min
supernat
use
cytokin
quantif
level
interleukin
il
kc
rant
determin
use
mous
bead
kit
millipor
billerica
accord
manufactur
instruct
experi
perform
filter
plate
result
analyz
luminex
system
qiagen
germantown
md
lung
remov
day
pi
fix
buffer
formalin
fix
lung
subsequ
embed
paraffin
section
slice
stain
hematoxylineosin
histopatholog
score
determin
two
independ
research
blind
experiment
data
semiquantit
scale
use
score
bronchial
endobronchi
peribronchi
perivascular
interstiti
pleural
intraalveolar
inflamm
previous
describ
lung
remov
day
pi
perfus
ml
endotoxinfre
pb
cederlan
burlington
incub
ml
mgml
collagenas
roch
nutley
nj
hank
balanc
salt
solut
hbss
wisent
quebec
qc
min
u
dnase
ad
lung
incub
anoth
min
tissu
disrupt
mechan
filter
red
blood
cell
lyse
use
ack
buffer
life
technolog
carlsbad
ca
cell
incub
fcblock
bd
bioscienc
franklin
lake
nj
fluorochromeconjug
antibodi
endotoxinfre
pb
contain
fb
hepe
min
wash
cell
fix
formaldehyd
endotoxinfre
pb
contain
actinomycin
cederlan
burlington
surfac
marker
antibodi
specif
murin
iaie
bd
bioscienc
franklin
lake
nj
biolegend
san
diego
ca
dye
biolegend
san
diego
ca
use
exclud
dead
cell
cell
analyz
use
bd
facscantoa
system
gate
posit
cell
base
fluoresc
minu
one
fmo
control
analys
perform
use
fc
express
softwar
statist
analys
perform
use
prism
softwar
weight
loss
pulmonari
cytokinechemokin
level
histopatholog
score
analyz
twoway
anova
lung
viral
titer
furin
express
level
analyz
use
student
ttest
cell
recruit
analyz
use
oneway
anova
figur
specif
agonist
antagonist
male
mice
effect
intralumen
administr
agonist
tfllrnh
inact
control
peptid
rllft
colon
effect
hmpv
infect
mice
plo
one
wwwplosoneorg
wildtyp
mice
intestin
permeabl
passag
macromolecul
credta
lumen
blood
observ
h
intracolon
administr
tfllr
rllft
per
group
group
p
significantli
differ
salin
control
peptid
rllft
treat
group
b
effect
intralumen
administr
agonist
tfllrnh
colon
mice
treat
antagonist
vehicl
intestin
permeabl
passag
macromolecul
credta
lumen
blood
observ
h
intracolon
administr
tfllr
rllft
per
group
group
p
significantli
differ
salinetr
group
tif
figur
weight
loss
hmpvinfect
mice
treat
antagonist
group
mice
infect
intranas
hmpv
tcid
mock
infect
simultan
treat
day
singl
daili
dose
one
two
antagonist
monitor
daili
weight
loss
mortal
day
horizont
bar
underneath
graphic
indic
time
durat
treatment
signific
differ
weight
loss
observ
mice
mice
untreat
mice
base
twoway
anova
p
p
p
arrow
number
indic
mice
reach
endpoint
sacrif
full
line
untreat
mice
dot
line
mice
tif
